Abstract: Uncertainty exists regarding cardiovascular (CV) safety of sulphonylureas (SUs) as reflected in package labels and treatment guidelines. This study evaluated clinical treatment practice for SUs by analysing prescription patterns for SUs relative to patient history of CV disease (CVD). Patients in Denmark initiating treatment with SU or other anti-hyperglycaemic drugs during 2006-12 were retrospectively identified using national health registries. Pre-existing (previous 12 years) overall CVD, coronary heart disease (CHD) and myocardial infarction (MI) were subsequently identified. Proportion of patients with pre-existing CVD was compared between new users of SU and new users of other anti-hyperglycaemic drugs. Diabetes is a chronic disease characterized by deficiencies in insulin secretion, insulin action or both, leading to hyperglycaemia and consequently increased risk of disabling and lifethreatening health complications [1]. Globally, around 415 million people are living with diabetes, a number that is expected to rise to 642 million by the year 2040. Approximately 90% have type 2 diabetes mellitus (T2DM), and the number of people with T2DM is currently increasing in all countries [1].
Diabetes is a chronic disease characterized by deficiencies in insulin secretion, insulin action or both, leading to hyperglycaemia and consequently increased risk of disabling and lifethreatening health complications [1] . Globally, around 415 million people are living with diabetes, a number that is expected to rise to 642 million by the year 2040. Approximately 90% have type 2 diabetes mellitus (T2DM), and the number of people with T2DM is currently increasing in all countries [1] .
Patients with diabetes are at two times to four times increased cardiovascular (CV) risk compared to individuals without diabetes [2] [3] [4] [5] . Conflicting results exist on the general effect of improved glycaemic control on CV risk in patients with diabetes. Also, there has been concern about the CV safety of certain anti-hyperglycaemic drugs [2] . This has led health authorities to require thorough CV safety evaluation through large prospective CV outcome trials or meta-analyses across the clinical development programme for all new antihyperglycaemic agents [6, 7] . As a consequence, there are currently a number of ongoing CV outcome trials in T2DM including drugs from several of the newer drug classes such as dipeptidyl-peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucoselinked transporter 2 (SGLT2) inhibitors [8] [9] [10] [11] .
For other drug classes, for example sulphonylureas (SUs) and thiazolidinediones, an association with increased CV risk has been found in a number of studies [2, 8, 12] . For SUs, the University Group Diabetes Program trial and several subsequent observational studies suggest a detrimental effect on CV risk of SUs versus metformin or placebo [13] [14] [15] [16] . In the UK Prospective Diabetes Study, the combined use of metformin and SU resulted in an increased mortality rate versus monotherapy [17] . On the other hand, several meta-analyses of randomized clinical trials have not shown an association between SUs and CV risk [8, 12, 18] . Recently, observational and retrospective studies have shown that CV risk is higher for SUs than for DPP-4 inhibitors [19, 20] . Importantly, part of the discrepancy may be due to differences in CV risk between individual SUs [12] . In particular, it has been shown that gliclazide may be associated with a more benign CV profile [15, 16, 21] , although a recent UK registry study indicated that this might not be the case [20] . Pre-clinical studies suggest that ischaemic pre-conditioning may be hampered by some but not all SUs [22] . These uncertainties about the CV safety of SUs are reflected in package labels and treatment guidelines around the world, including the Danish diabetes guidelines [23] [24] [25] [26] .
Given the uncertainty about CV safety of SUs, we wanted to evaluate current clinical treatment practice for SUs in relation to a potential CV risk. Such information can be generated by obtaining information on prescription patterns for SUs relative to patient history of CV disease (CVD). Therefore, the purpose of the present registry-based population study was to investigate the prescription patterns for SUs in Denmark from 2006 to 2012 in relation to pre-existing CVD, and to compare the prevalence of CVD in patients initiating SU treatment with that of patients initiating other anti-hyperglycaemic drugs than SUs. The cross-sectional study was based on records from the internationally well-recognized Danish national health registries.
Methods
Registry data sources. This study used data extracted from national . The registries can be merged at an individual level using the unique permanent civil registration number which is assigned to all residents in Denmark. National Danish health registries are widely used for registry analyses given their relatively high degree of completeness and long temporal coverage. The Danish National Health Service provides health care for all residents providing free access to hospitals and general practitioners and refunds part of prescription medication costs. Prior to data extraction and analysis, approval was obtained from the Danish Data Protection Agency. No informed consent was required.
Patient population. All patients receiving SUs in the period of 2006-12 were retrospectively identified per year using the Anatomical Therapeutic Chemical (ATC) code A10BB. New SU users were defined as those with no record of SU prescription 1 year prior to the date of the first prescription (the index date). As a reference, new users of any other anti-hyperglycaemic drugs, excluding insulin, were identified by the same approach using the ATC code A10B, excluding A10BB (table S4) .
Prevalence of CVD. Pre-existing overall CVD, coronary heart disease (CHD) and myocardial infarction (MI) were identified by searching for the ICD-10 codes I00-I99 (all CVD), I20-I25 and I46 (CHD) and I21-I22 (MI) within the 12 years prior to the year of the SU/other anti-hyperglycaemic drug start date (the index date). Thus, all events registered occurred less than 12 years from the index date, irrespective of any prior event.
Alternative SU definition. As it has been shown that gliclazide may be associated with a more benign CV profile [15, 16, 21] , although not a consistent finding [20] , analyses were also conducted with SUs excluding gliclazide, that is using the ATC code A10BB excluding A10BB09.
Statistical analyses. To investigate the prescription patterns for SUs in Denmark from 2006 to 2012, the number of new prescription drug users was identified per year for SUs (including and excluding gliclazide), as well as for any other anti-hyperglycaemic drugs (excluding insulin). To compare the CVD characteristics of patients initiating SU treatment with those of patients initiating other anti-hyperglycaemic drugs than SUs, the proportion of patients with pre-existing CVD (i.e. overall CVD, CHD and MI, respectively) was compared between new SU users and new users of other antihyperglycaemic drugs during each year from 2006 to 2012. All statistical analyses were carried out using Statistical Analysis System (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA). fig. 2A) . The proportion of new SU users with pre-existing CHD was also larger than the corresponding proportion among patients initiating treatment with other anti-hyperglycaemic drugs ( fig. 2B ). The proportion of new SU users with pre-existing MI was numerically greater compared to the corresponding (table 2) .
Results

Patient
Discussion
The current registry-based population study showed that initiation of SU treatment in Denmark declined by 63% from 2006 to 2012. During the same period, a minor numerical increase occurred in the proportion of patients with pre-existing CVD among new SU users, which approached 50% in 2012. Moreover, the proportion of new SU users with any pre-existing CVD was consistently higher (46.9-49.8% for any CVD) than the corresponding proportion among patients initiating other anti-hyperglycaemic drugs. Altogether, these findings suggest that any uncertainty about the CV safety of SUs has not prompted clinicians to use precautionary principles in their prescriptions of SUs to patients with pre-existing CVD. Rather, the overall decline in number of patients initiating SU treatment has likely been influenced by the unfavourable profile of increased hypoglycaemia rates and weight gain associated with SUs compared to the profiles of newer drug classes such as DPP-4 inhibitors and GLP-1 receptor agonists introduced in the same time period [27] . An increased risk of adverse CV events induced by SUs could be explained either by the ability of SUs to inhibit K ATP channels in cardiac myocytes and smooth muscle cells leading to inhibition of ischaemic conditioning, or by the fact that hypoglycaemia, a known side effect of SU treatment, has been linked to adverse CV effects [12] . It is reassuring that the uncertainty about CV safety of SUs is stated in some package labels and diabetes treatment guidelines around the world [23] [24] [25] [26] . However, the current findings suggest that there is a need to increase physicians' awareness of and adherence to current diabetes treatment guidelines regarding caution of SU use in patients already at high CV risk, including patients with CVD history. Further, in support of this, a recent study based on the National Ambulatory Medical Care Survey in the USA found that prescription of SU was more frequent in patients with diabetes aged ≥ 70 years compared to those aged 18-40 years; that is, SU prescription was most predominant in those patients at highest risk of CV events [28] . Other studies suggest that physicians may disregard scientific data and/or guidelines when prescribing anti-hyperglycaemic drugs. In a survey, among 383 practicing physicians treating patients with diabetes in the USA, close to 50% answered that they were unfamiliar with the American Diabetes Association (ADA)/ European Association for the Study of Diabetes (EASD) and American Association of Clinical Endocrinologists (AACE) guidelines or that they did not rely on these guidelines [29] . Among the same physicians, diabetes-related knowledge and the quality of clinical decision-making were lower compared to those physicians integrating the diabetes guidelines in their clinical practice [29] . In a cross-sectional study of 363 patients with diabetes at 32 practices in the Netherlands, adherence to national diabetes guidelines was suboptimal (adherence in <70% of patients/practices) for several indicators of care [30] . In a retrospective cohort study in the UK of 7133 new users of a GLP-1 receptor agonist, only 25% of patients initiated GLP-1 receptor agonist therapy in accordance with the National Institute for Health and Care Excellence (NICE) guidelines [31] . Among 301 patients with diabetes treated with metformin in Australia, 21-31% received metformin in the presence of contraindications or in excessive dosage relative to guidelines [32] . Finally, in a retrospective analysis of 95,330 patients from a US health insurance claims database, diabetes treatment modification was according to ADA guidelines in only 39% of patients [30] . Moreover, the odds of achieving glycated haemoglobin (HbA 1c ) <7% were five times higher in those patients treated according to ADA guidelines [33] , showing that adherence to guidelines may be predictive of successful health outcomes, although such a clear relationship is not always found [30] .
A broader acknowledgement of a potentially increased CV risk associated with some anti-hyperglycaemic drugs and a better integration into clinical treatment practice might be achieved if different diabetes treatment guidelines provided consistent, clear messages on this issue. While the Danish diabetes guidelines directly refer to studies investigating the CV risk of SU treatment [26] , and certain guidelines mention in general that uncertainty exists about the CV risk associated with SUs [24, 25] , other diabetes guidelines do not mention this issue [34, 35] . As there is a current uncertainty in the literature about a potential CV risk of SU treatment, we suggest that the uncertainties are reflected clearly in guidelines to all groups of care providers. This would also be in line with the updated position statement from the ADA/EASD focusing on the patient-centred approach and describing that optimal treatment of T2DM must take into account the various comorbidities frequently observed particularly in elderly patients [36] . A previous example of a guideline change temporally associated with a change in treatment practice comes from a study in 1279 new users of oral antidiabetic drugs in Canada between 2003 and 2011 [37] . After the Canadian Diabetes Association recommended metformin as the starting therapy for all patients newly diagnosed with T2DM in an updated guideline from 2008, the incident use of metformin increased from 89.7% to 94.6% [37] . In the case of rosiglitazone, increased CV risk reported in a meta-analysis led to addition of a warning to the rosiglitazone label by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which induced an abrupt decline in the use of rosiglitazone both in the USA and in European countries [38, 39] . Another example was the identification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients treated with natalizumab, which led to a temporary withdrawal from the market and subsequent reintroduction accompanied by pharmacovigilance programmes as well as diagnostic and treatment monitoring algorithms allowing for early withdrawal of natalizumab in potential cases of PML [40] . These examples show that changing a product label or a treatment guideline or generally increasing awareness of a potential adverse drug effect carries the potential to impact the practice of physicians leading to improved safety of the patients.
The robustness of the results reported in the present study is supported by the fact that changes in SU definition or type of CVD did not alter the conclusions. Another strength of the present study is that selection bias was avoided due to use of the nationwide Danish health registries. The Registry for Medicinal Product Statistics is linked to the system of partial reimbursement of prescription medication costs provided by the Danish National Health Service and is considered highly valid [41] . The National Patient Registry is considered the most comprehensive of its kind internationally [42, 43] , and its validity is supported for instance with a specificity value of >90% for first-time MI [44] . The current study carries some limitations inherent for retrospective observational studies, such as unmeasured confounding. Moreover, any conclusions on causal relationships from the present study should be drawn with caution.
In conclusion, the findings of the current study indicate that patients' pre-existing CVD did not decrease clinicians' relative prescriptions of SUs in Denmark from 2006 to 2012, despite a potential CV risk associated with the use of SUs. 
